“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Commentary on “Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: Toxicity and outcome from a dose escalation pilot study.” T. Zilli, S. Jorcano, M. Rouzaud, G. Dipasquale, P. Nouet, J.I. Toscas, N. Casanova, H. Wang, L. Escudé, M. Mollà, D. Linero, D.C. Weber, R. Miralbell, Service de Radio-oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland

Commentary on “Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: Toxicity and outcome from a dose escalation pilot study.” T. Zilli, S. Jorcano, M. Rouzaud, G. Dipasquale, P. Nouet, J.I. Toscas, N. Casanova, H. Wang, L. Escudé, M. Mollà, D. Linero, D.C. Weber, R. Miralbell, Service de Radio-oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland To evaluate the toxicity and preliminary outcome of patients with localized prostate cancer treated with twice-weekly hypofractionated intensity-modulated radiotherapy (IMRT). Between 2003 and 2006, 82 prostate cancer patients with a nodal involvement risk ≤20% (Roach index) have been treated for the prostate with or without seminal vesicles with 56 Gy (4 Gy/fraction twice weekly) and an overall treatment time of 6.5 weeks. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) grading system. Median follow-up was 48 months (range, 9–67 months). All patients completed the treatment without interruptions. No patient presented with Grade ≥3 acute GU or GI toxicity. Of the patients, 4% presented with Grade 2 GU or GI persistent acute toxicity 6 weeks after treatment completion. The estimated 4-year probability of Grade ≥2 late GU and GI toxicity-free survival were 94.2% ± 2.9% and 96.1% ± 2.2%, respectively. One patient presented with grade 3 GI and another patient with Grade 4 GU late toxicity, which were transitory in both cases. The 4-year actuarial biochemical relapse-free survival was 91.3% ± 5.9%, 76.4% ± 8.8%, and 77.5% ± 8.9% for low-, intermediate-, and high-risk groups, respectively. In patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Urologic Oncology: Seminars and Original Investigations Elsevier
Loading next page...
 
/lp/elsevier/commentary-on-twice-weekly-hypofractionated-intensity-modulated-bM9Fe34x7w

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.